Last updated 2026-07-26
- Raised $8.2M Undisclosed Round led by Club 100 Plus, Mar 2021
- Raised Undisclosed Round led by EMV capital, Dec 2023
- Raised Undisclosed Round led by Katao Venture Partners, Nov 2022
Total raised
$8.2M
Last: Undisclosed Round 2024-01
Stage
Seed
Founded
2014
Headcount
26
HQ
Kefar Sava, Israel
Sector
Health Tech & Life Sciences
About
QuantalX NeuroScience is redefining brain healthcare by empowering clinicians with real-time, accurate insights to accelerate decision-making and close critical diagnostic gaps for neurological conditions. Their Delphi-MD™ system is a non-invasive, radiation-free, and easy-to-use device that captures functional responses in real-time, providing accessible brain health insights across various care settings. The company aims to set a new gold standard in neurodiagnostics, driving better outcomes and a higher quality of life across the neurological spectrum. QuantalX solutions are used in clinics and research sites across Europe, Asia, and North America.
Funding history · 4 rounds · $8.2M total
2023-12
Undisclosed Round
Undisclosed
★ EMV capital
2022-11
Undisclosed Round
Undisclosed
★ Katao Venture PartnersKeiretsu Forum Northwest
2021-03
Undisclosed Round
$8.2M
★ Club 100 Plus★ Keiretsu Forum Northwest
2014-12
Grant
Undisclosed
Headcount over time
From 2 (2018-12) to 24 (2026-03) · +22 (+1100%) · 22 points · source: Finder history + radar grounding
Q&A
- What is QuantalX NeuroScience's primary product?
- QuantalX NeuroScience develops the Delphi-MD™ system, an FDA De Novo–authorized device that uses Direct Electrophysiological Imaging to assess brain network function in real-time.
- When did QuantalX NeuroScience secure FDA clearance for its Delphi Stimulator?
- QuantalX NeuroScience secured FDA clearance for its Delphi Stimulator on November 12, 2024, to advance direct brain health diagnosis at the point of care.
- Has QuantalX NeuroScience received CE MDR approval for its device?
- Yes, QuantalX NeuroScience announced CE MDR approval for its Delphi-MD brain health assessment device on February 12, 2025, making it available in the EU.
- When did QuantalX NeuroScience receive FDA De Novo clearance for the Delphi-MD System?
- QuantalX NeuroScience received FDA De Novo clearance for its Delphi-MDTM System on November 18, 2025, establishing a new modality of brain function assessment.
- Which investor participated in QuantalX NeuroScience's Seed round?
- Katao Venture Partners participated in QuantalX NeuroScience's Seed round in December 2022.
- How many employees does QuantalX NeuroScience have?
- QuantalX NeuroScience has 26 employees, falling within the 11-50 employee bucket.
- With whom did QuantalX NeuroScience partner to advance brain health across the lifespan?
- In May 2024, QuantalX NeuroScience partnered with the Sheba Longevity Center to advance brain health across the lifespan.
- When did QuantalX NeuroScience secure a dedicated reimbursement code for the Delphi-MD test?
- QuantalX NeuroScience secured a dedicated reimbursement code for the Delphi-MD test on November 2, 2023, to advance improved brain health.
Team · 2
Iftach Dolev
Founder · CEO and Founder
Hilla Fogel
Founder · CTO and Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesDigital HealthcareDigital Medical Diagnostics
Technologies
Simulation & Imaging
Target customers
Healthcare & Life SciencesHealthcareProvidersLife Sciences
Business model
B2B
Highlights
1 PatentsVerified
Tags
brain-disorderdoctorshealthcarepersonalizationhealthcare-providersneurologyparkinsonchronic-patientstreatmentsdiagnosticsmedical-devicesneuro-stimulationalzheimers-diseasemonitoringsignal-processingcomputer-visionmental-healthneurovascularneurosurgeryepilepsynon-invasivechronic-painneurosciencepsychiatry
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | quantalx.com |
|---|---|
| linkedin.com/company/77652362 | |
| facebook.com/profile.php?id=100070603987516 |
Identifiers & details
| Legal name | QuantalX Neuroscience Ltd. |
|---|---|
| Former names | NIBS NeuroScience Technologies |
| Founded | 2014 |
| Employees (exact) | 26 |
Radar intelligence
Patents
| EPO | 8 |
|---|
Web history (Wayback)
| Domain | quantalx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 5 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515049260 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2014-03-12 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 8 — shares_capital (2), other (1), charge (2), annual_report (2), people (1) |
| Registered address | הטחנה 1 כפר סבא |
Recent registry events
| Date | Event |
|---|---|
| 2026-07-21 | שינוי בהרכב הון - מניות-פיצול מניה |
| 2026-07-21 | שינוי בתקנון |
| 2026-05-17 | סילוק שעבוד |
| 2026-05-14 | רישום שעבוד |
| 2026-07-09 | הקצאת מניות |
| 2026-07-05 | דו~ח שנתי-עדכון מנהלים |
| 2026-07-05 | דו~ח שנתי-עדכון בעלי מניות |
| 2026-02-03 | עדכון בעלי תפקידים |